JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

A

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

A

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

A

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

A

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

A

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

Search

Simulations Plus Inc

Avatud

SektorTervishoid

14.36 -5.09

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.08

Max

15.13

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Dividenditootlus

0.48

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+5.33% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.24%

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

51M

302M

Eelmine avamishind

19.45

Eelmine sulgemishind

14.36

Uudiste sentiment

By Acuity

6%

94%

7 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. apr 2026, 23:33 UTC

Tulu

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. apr 2026, 22:40 UTC

Tulu

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:11 UTC

Tulu

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. apr 2026, 21:01 UTC

Tulu

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. apr 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. apr 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. apr 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. apr 2026, 23:16 UTC

Tulu

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. apr 2026, 23:15 UTC

Tulu

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. apr 2026, 22:52 UTC

Tulu

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. apr 2026, 22:51 UTC

Tulu

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. apr 2026, 22:30 UTC

Tulu

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. apr 2026, 22:30 UTC

Tulu

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. apr 2026, 22:29 UTC

Tulu

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. apr 2026, 22:27 UTC

Tulu

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. apr 2026, 22:06 UTC

Market Talk
Tulu

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:47 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:37 UTC

Tulu

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. apr 2026, 21:34 UTC

Tulu

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. apr 2026, 21:29 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:20 UTC

Market Talk
Tulu

Tesla Expands Manufacturing to Chips -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

5.33% tõus

12 kuu keskmine prognoos

Keskmine 16 USD  5.33%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

7 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat